Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 5 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

1
Player Avatar YoungScientist63 (95.22) Submitted: 1/18/2007 6:10:42 PM : Underperform Start Price: $26.28 AEZS Score: +116.46

Uhhhh............ it will just do bad. :) --A Scientist

Report this Post 2 Replies
Member Avatar EnigmaDude (96.33) Submitted: 1/5/2011 10:30:59 AM
Recs: 0

well that's convincing.

Member Avatar brigar6 (< 20) Submitted: 11/1/2011 11:12:32 PM
Recs: 0

ENIGMA, NOT THAT IT MATTERS BUT HAS ANYONE POINTED OUT TO YOU THE POST YOU JUST COMMENTED ON IS 4 YRS OLD
YOU MUST STILL BE ON PHONE LINE INTERNET, OR REALLY TAKE YOUR DD TO THE NEXT LEVEL OF RESEARCH

Featured Broker Partners


Advertisement